Royalty Pharma (RPRX) Cash from Investing Activities Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) Cash from Investing Activities Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -41.67% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -157.08% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -589.38% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -89.24% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 26.37% |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.37% |
| Mar 31, 2026 | -194.83% |
| Dec 31, 2025 | -67.69% |
| Sep 30, 2025 | 19.65% |
| Jun 30, 2025 | 65.07% |
| Mar 31, 2025 | 681.55% |
| Dec 31, 2024 | 49.45% |
| Sep 30, 2024 | -164.66% |
| Jun 30, 2024 | -1,308.06% |
| Mar 31, 2024 | 84.49% |
| Dec 31, 2023 | -341.16% |
| Sep 30, 2023 | 68.38% |
| Jun 30, 2023 | -110.20% |
| Mar 31, 2023 | -5,102.47% |
| Dec 31, 2022 | 175.18% |
| Sep 30, 2022 | -68.56% |
| Jun 30, 2022 | -123.92% |
| Mar 31, 2022 | 101.86% |
| Dec 31, 2021 | 33.73% |
| Sep 30, 2021 | 8.12% |